InflaRx (IFRX) Stock Forecast & Price Target

Compare

733 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IFRX Analyst Ratings

Moderate Buy

2 Buy

1 Hold

0 Sell

Based on 3 analysts giving stock ratings to

InflaRx

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IFRX Stock 12 Month Forecast

Average Price Target

$4.00

▲(210.08% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for InflaRx in the last 3 months. The average price target is $4.00 with a high forecast of $6.00 and a low forecast of $2.00. The average price target represents a 210.08% change from the last price of $1.29.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","3":"$3","5":"$5","7":"$7","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.75,2.076923076923077,2.4038461538461537,2.730769230769231,3.0576923076923075,3.3846153846153846,3.7115384615384617,4.038461538461538,4.365384615384615,4.6923076923076925,5.019230769230769,5.346153846153847,5.673076923076923,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.75,1.9230769230769231,2.0961538461538463,2.269230769230769,2.4423076923076925,2.6153846153846154,2.7884615384615383,2.9615384615384617,3.1346153846153846,3.3076923076923075,3.480769230769231,3.6538461538461537,3.8269230769230766,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.75,1.7692307692307692,1.7884615384615385,1.8076923076923077,1.8269230769230769,1.8461538461538463,1.8653846153846154,1.8846153846153846,1.9038461538461537,1.9230769230769231,1.9423076923076923,1.9615384615384617,1.9807692307692308,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.41,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.43,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.39,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.39,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.86,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.75,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$6.00

Average Price Target$4.00

Lowest Price Target$2.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew Keller

H.C. Wainwright

Buy

365.12%

Upside

Reiterated

09/17/25

H.C. Wainwright Remains a Buy on InflaRx (IFRX)

Joseph Schwartz

Leerink Partners

Buy

55.04%

Upside

Reiterated

08/07/25

Analysts Offer Insights on Healthcare Companies: Replimune Group (NASDAQ: REPL), Pliant Therapeutics (NASDAQ: PLRX) and InflaRx (NASDAQ: IFRX)We are updating our model to reflect InflaRx's (IFRX, OP) 2Q25 financial results and corporate update; focus remains on the upcoming Ph.2a readout in HS and CSU, now expected by the end of September to early November (previously summer 2025). Following the recommendation to stop the Ph.3 trial (NCT05964413) for vilobelimab (monoclonal anti-human complement factor C5a antibody) in pyoderma gangrenosum (PG) due to futility (here), the focus for the company has shifted entirely to IFRX's now lead asset INF904, an oral complement C5a receptor (C5aR) inhibitor, in development for hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU).

Sam Slutsky

LifeSci Capital

―

Hold

―

Reiterated

08/07/25

InflaRx's Hold Rating Amid Trial Delays and Uncertain Clinical Data

Ryan Deschner

Raymond James

$13→$2

Buy

55.04%

Upside

Reiterated

05/29/25

InflaRx's Strategic Shift to INF904: A Promising Focus Amidst Early-Stage Uncertainty

Yatin Suneja

Guggenheim

$10

Buy

675.19%

Upside

Reiterated

05/28/25

Guggenheim reiterates Buy Rating on Inflarx NV (IFRX)Guggenheim analyst Yatin Suneja reiterated a Buy rating and $10.00 price target on Inflarx NV (NASDAQ: IFRX).

Andreas Argyrides

Oppenheimer

$6→$3

Buy

132.56%

Upside

Reiterated

05/28/25

InflaRx (IFRX) Gets a Buy from Oppenheimer

Steven Seedhouse

Cantor Fitzgerald

$10

Buy

675.19%

Upside

Initiated

04/28/25

Cantor Fitzgerald starts Inflarx NV (IFRX) at OverweightCantor Fitzgerald analyst Steven Seedhouse initiates coverage on Inflarx NV (NASDAQ: IFRX) with a Overweight rating and a price target of $10.00.

Unknown Analyst

Lucid Capital

Not Ranked

Lucid Capital

$10

Buy

675.19%

Upside

Initiated

11/19/24

InflaRx initiated with a Buy at Lucid CapitalInflaRx initiated with a Buy at Lucid Capital

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew Keller

H.C. Wainwright

Buy

365.12%

Upside

Reiterated

09/17/25

H.C. Wainwright Remains a Buy on InflaRx (IFRX)

Joseph Schwartz

Leerink Partners

Buy

55.04%

Upside

Reiterated

08/07/25

Sam Slutsky

LifeSci Capital

―

Hold

―

Reiterated

08/07/25

InflaRx's Hold Rating Amid Trial Delays and Uncertain Clinical Data

Ryan Deschner

Raymond James

$13→$2

Buy

55.04%

Upside

Reiterated

05/29/25

InflaRx's Strategic Shift to INF904: A Promising Focus Amidst Early-Stage Uncertainty

Yatin Suneja

Guggenheim

$10

Buy

675.19%

Upside

Reiterated

05/28/25

Guggenheim reiterates Buy Rating on Inflarx NV (IFRX)Guggenheim analyst Yatin Suneja reiterated a Buy rating and $10.00 price target on Inflarx NV (NASDAQ: IFRX).

Andreas Argyrides

Oppenheimer

$6→$3

Buy

132.56%

Upside

Reiterated

05/28/25

InflaRx (IFRX) Gets a Buy from Oppenheimer

Steven Seedhouse

Cantor Fitzgerald

$10

Buy

675.19%

Upside

Initiated

04/28/25

Unknown Analyst

Lucid Capital

Not Ranked

Lucid Capital

$10

Buy

675.19%

Upside

Initiated

11/19/24

InflaRx initiated with a Buy at Lucid CapitalInflaRx initiated with a Buy at Lucid Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering InflaRx

1 Month

xxx

Success Rate

7/19 ratings generated profit

Average Return

+5.32%

initiated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 36.84% of your transactions generating a profit, with an average return of +5.32% per trade.

3 Months

xxx

Success Rate

7/18 ratings generated profit

Average Return

+1.58%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 38.89% of your transactions generating a profit, with an average return of +1.58% per trade.

1 Year

Steven SeedhouseCantor Fitzgerald

Success Rate

5/19 ratings generated profit

Average Return

-17.86%

initiated a buy rating 5 months ago

Copying Steven Seedhouse's trades and holding each position for 1 Year would result in 26.32% of your transactions generating a profit, with an average return of -17.86% per trade.

2 Years

xxx

Success Rate

3/18 ratings generated profit

Average Return

-24.00%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 16.67% of your transactions generating a profit, with an average return of -24.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IFRX Analyst Recommendation Trends

Rating

Apr 25

May 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IFRX has received 3 Buy Ratings, 11 Hold Ratings, and 2 Sell Ratings. IFRX average Analyst price target in the past 3 months is 4.00.

Each month's total comprises the sum of three months' worth of ratings.

IFRX Financial Forecast

IFRX Earnings Forecast

Next quarter’s earnings estimate for IFRX is -$0.18 with a range of -$0.26 to -$0.09. The previous quarter’s EPS was -$0.25. IFRX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.11% of the time in the same period. In the last calendar year IFRX has Outperformed its overall industry.

IFRX Sales Forecast

Next quarter’s sales forecast for IFRX is $80.76K with a range of $0.00 to $359.31K. The previous quarter’s sales results were $44.73K. IFRX beat its sales estimates 33.33% of the time in past 12 months, while its overall industry beat sales estimates 47.50% of the time in the same period. In the last calendar year IFRX has Outperformed its overall industry.

IFRX Stock Forecast FAQ

What is IFRX’s average 12-month price target, according to analysts?

Based on analyst ratings, InflaRx NV’s 12-month average price target is 4.00.

What is IFRX’s upside potential, based on the analysts’ average price target?

InflaRx NV has 210.08% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IFRX a Buy, Sell or Hold?

InflaRx NV has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.

What is InflaRx NV’s price target?

The average price target for InflaRx NV is 4.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $6.00 ,the lowest forecast is $2.00. The average price target represents 210.08% Increase from the current price of $1.29.

What do analysts say about InflaRx NV?

InflaRx NV’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of IFRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

InflaRx (IFRX) Stock Forecast & Price Target

IFRX Analyst Ratings

IFRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering InflaRx

IFRX Analyst Recommendation Trends

IFRX Financial Forecast

IFRX Earnings Forecast

IFRX Sales Forecast

IFRX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts